Lucid Diagnostics Inc. (LUCD) stock
LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3034% above fair value
$0.40+0.00 (+0.30%)
Close on Nov 17, 2026Market cap $81.09MP/E –Yield –
Lucid Diagnostics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lucid Diagnostics's price to sales ratio was 13.4× on Nov 11, 2026, against 31.5× a year earlier. Over the last 5 years it ranged from 10.1× to 261.2×, with a median of 32.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.4× | −19.1 |
| 2025 | Dec 31, 2025 | 32.4× | +22.4 |
| 2024 | Dec 31, 2024 | 10.1× | −29.7 |
| 2023 | Dec 29, 2023 | 39.8× | −49.3 |
| 2022 | Dec 30, 2022 | 89.1× | – |
See a number that looks wrong?